- Home
- MQY vs TRVI Comparison
MQY vs TRVI Comparison
Compare MQY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- TRVI
- Stock Information
- Founded
- MQY 1994
- TRVI 2011
- Country
- MQY United States
- TRVI United States
- Employees
- MQY N/A
- TRVI N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- MQY Finance
- TRVI Health Care
- Exchange
- MQY Nasdaq
- TRVI Nasdaq
- Market Cap
- MQY 776.5M
- TRVI 725.7M
- IPO Year
- MQY N/A
- TRVI 2019
- Fundamental
- Price
- MQY $11.06
- TRVI $7.33
- Analyst Decision
- MQY
- TRVI Strong Buy
- Analyst Count
- MQY 0
- TRVI 9
- Target Price
- MQY N/A
- TRVI $19.94
- AVG Volume (30 Days)
- MQY 184.8K
- TRVI 1.8M
- Earning Date
- MQY 01-01-0001
- TRVI 08-11-2025
- Dividend Yield
- MQY 4.73%
- TRVI N/A
- EPS Growth
- MQY N/A
- TRVI N/A
- EPS
- MQY N/A
- TRVI N/A
- Revenue
- MQY N/A
- TRVI N/A
- Revenue This Year
- MQY N/A
- TRVI N/A
- Revenue Next Year
- MQY N/A
- TRVI N/A
- P/E Ratio
- MQY N/A
- TRVI N/A
- Revenue Growth
- MQY N/A
- TRVI N/A
- 52 Week Low
- MQY $9.82
- TRVI $2.36
- 52 Week High
- MQY $12.52
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- MQY 59.00
- TRVI 59.58
- Support Level
- MQY $10.80
- TRVI $7.31
- Resistance Level
- MQY $10.90
- TRVI $7.74
- Average True Range (ATR)
- MQY 0.09
- TRVI 0.39
- MACD
- MQY 0.01
- TRVI 0.02
- Stochastic Oscillator
- MQY 100.00
- TRVI 48.00
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.